Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.63 |
| ▸ | JAK1 | P23458 | 5/20 | 0.63 |
| ▸ | CDK7 | P50613 | 7/20 | 0.54 |
| ▸ | ULK1 | O75385 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31240484 | 1.00 | JAK2 (0.63) | JAK2JAK1CDK7ULK1DYRK1A | |
| SCHEMBL31240407 | 0.90 | JAK2 (0.63) | JAK2JAK1CDK7ULK1DYRK1A | |
| SCHEMBL26686340 | 0.87 | JAK2 (0.56) | JAK2JAK1ULK1DYRK1A | |
| SCHEMBL26686370 | 0.86 | JAK2 (0.61) | JAK2JAK1ULK1DYRK1AKIT | |
| SCHEMBL31420124 | 0.86 | JAK2 (0.61) | JAK2JAK1ULK1DYRK1AKIT | |
| SCHEMBL26685861 | 0.85 | JAK2 (0.56) | JAK2JAK1DYRK1AKITFLT3 | |
| SCHEMBL30633352 | 0.85 | JAK2 (0.56) | JAK2JAK1DYRK1AKITFLT3 | |
| SCHEMBL31240493 | 0.84 | WNT3A (0.57) | JAK2DYRK1A | |
| SCHEMBL31240431 | 0.83 | NPC1 (0.48) | JAK2JAK1ULK1DYRK1AMAPK10 | |
| SCHEMBL30633307 | 0.82 | MAPK1 (0.59) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | claimed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | claimed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | JAK2 207/4885JAK1 95/4885CDK7 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.